A phase 1 / 2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. - Nademanee,A.; Forman,S.; Molina,A.; Fung,H.; Smith,D.; Kwok,C.; Yamauchi,D. (Blood, 2005)